Edgewise Therapeutics, Inc., (Nasdaq: EWTX), a leading muscle disease biopharmaceutical company, today announced that management will present at the Cantor Virtual Muscular Dystrophy Symposium on Tuesday, April 2, 2024, at 2:20 pm ET.

The presentation will be webcast live; a link for the webcast can be found on the Edgewise events page and will be accessible for replay following the presentation. It is recommended that users connect to the webcast several minutes prior to the start to ensure a timely connection.

About Edgewise Therapeutics

Edgewise Therapeutics is a leading muscle disease biopharmaceutical company developing novel therapeutics for muscular dystrophies and serious cardiac conditions. The Company’s deep expertise in muscle physiology is driving a new generation of first-in-class therapeutics. Sevasemten (EDG-5506) is an orally administered skeletal myosin inhibitor in clinical trials in patients with Becker, Duchenne, and Limb-Girdle muscular dystrophies as well as McArdle Disease. EDG-7500, currently in a Phase 1 trial, is a novel cardiac sarcomere modulator for the treatment of HCM and other disorders of cardiac diastolic dysfunction. The entire team at Edgewise is dedicated to our mission: changing the lives of patients and families affected by serious muscle diseases. To learn more, go to: www.edgewisetx.com or follow us on LinkedIn, X (formerly Twitter), Facebook, Instagram and Threads.

Edgewise Contacts Investors: Michael Carruthers, Chief Financial Officer ir@edgewisetx.com Media: Maureen Franco, VP Corporate Communications media@edgewisetx.com

Grafico Azioni Edgewise Therapeutics (NASDAQ:EWTX)
Storico
Da Nov 2024 a Dic 2024 Clicca qui per i Grafici di Edgewise Therapeutics
Grafico Azioni Edgewise Therapeutics (NASDAQ:EWTX)
Storico
Da Dic 2023 a Dic 2024 Clicca qui per i Grafici di Edgewise Therapeutics